1
Degnan Andrew P, Tora George O, Han Ying, Ramkumar Rajamani, Denhart Derek J, Ditta Jonathan L, Gillman Kevin W: 4,4-disubstituted piperidine derivatives as nk-i and serotonin transporter inhibitors. Bristol Myers Squibb Company, Degnan Andrew P, Tora George O, Han Ying, Ramkumar Rajamani, Denhart Derek J, Ditta Jonathan L, Gillman Kevin W, EPPERSON James, October 25, 2007: WO/2007/121389 (4 worldwide citation)

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.


2
Sheldon Hiebert, Michael S Bowsher, Ramkumar Rajamani, Rongti Li, Paul Michael Scola: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, Mary K VanAtten, October 22, 2013: US08563505 (2 worldwide citation)

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


3
Sheldon Hiebert, Ramkumar Rajamani, Li Qiang Sun, Eric Mull, Eric P Gillis, Michael S Bowsher, Qian Zhao, Nicholas A Meanwell, Kishore V Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P V K Suresh Babu, Paul Michael Scola: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, February 17, 2015: US08957203 (1 worldwide citation)

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


4
Vivekananda M Vrudhula, Senliang Pan, Ramkumar Rajamani, John E Macor, Joanne J Bronson, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu: Aryl ether-base kinase inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, April 22, 2014: US08703953 (1 worldwide citation)

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.


5
Sheldon Hiebert, Ramkumar Rajamani, Li Qiang Sun, Eric Mull, Eric P Gillis, Michael S Bowsher, Qian Zhao, Nicholas A Meanwell, Kishore V Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P V K Suresh Babu, Paul Michael Scola: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, December 27, 2016: US09527885

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


6
Ramkumar Rajamani, Kishore V Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, Nicholas A Meanwell, Paul Michael Scola: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, April 8, 2014: US08691757

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


7
Alan Xiangdong Wang, Ramkumar Rajamani, Paul Michael Scola: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, October 25, 2011: US08044087

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


8
Vivekananda M Vrudhula, Senliang Pan, Ramkumar Rajamani, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu, Tarun Kumar Maishal, Jonathan L Ditta, Carolyn Diane Dzierba, Joanne J Bronson, John E Macor: Aryl lactam kinase inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, December 2, 2014: US08901305

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.


9
Vivekananda M Vrudhula, Senliang Pan, Ramkumar Rajamani, John E Macor, Joanne J Bronson, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu: Aryl ether-base kinase inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, March 3, 2015: US08969564

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.


10
Andrew P Degnan, Kevin W Gillman, Derek J Denhart, Jonathan L Ditta, Ramkumar Rajamani, Ying Han, George O Tora: NK-1 and serotonin transporter inhibitors. Bristol Meyers Squibb Company, James Epperson, February 26, 2013: US08383821

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.